Literature DB >> 12750262

Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.

XiaoHe Yang1, Susan M Edgerton, Stanley D Kosanke, Terza L Mason, Kathy M Alvarez, Naxin Liu, Robert T Chatterton, Bolin Liu, Qi Wang, Aeree Kim, Satya Murthy, Ann D Thor.   

Abstract

Exogenous and dietary estrogens have been associated with modification of breast cancer risk. Mammary cancer model systems can be used to explore interactions between specific transgenes, and hormonal and dietary factors. Transgenic mice bearing the rat wild-type erbB-2 gene were used to study the effects of short-term hormonal exposure [17beta-estradiol (E2) or tamoxifen] or a soy meal diet on mammary carcinogenesis. In mice fed a casein diet, mammary tumors developed at an earlier age after short-term E2 exposure during the early reproductive period. The median mammary tumor latency was shortest (29 weeks) for the high-dose estrogen as compared with the lowest dose of E2 treated or placebo control mice (33 and 37 weeks, respectively). The timing of short-term E2 exposure was also important, with the most significant changes observed in mice exposed to E2 between 8 and 18 weeks of age. E2 exposure was associated with the subsequent development of more aggressive tumors as determined by histologic grade, multifocal tumor development, stromal invasion, and pulmonary metastasis. In contrast, short-term tamoxifen-exposed mice generally failed to develop mammary tumors by 60 weeks of age. Mice fed a soy meal diet developed mammary tumors at a later age than casein-fed animals treated with E2 or placebo, whereas no differences were observed by diet for the tamoxifen-treated mice. Mammary tumor prevention was >80% in tamoxifen-treated mice on either diet. Novel histologic tumor types were identified, suggesting greater phenotypic diversity than described previously. Benign mammary gland morphogenesis was also significantly altered by short-term hormonal exposure or dietary factors, consistent with the modification of mammary tumor risk in specific treatment groups. Estrogenic modulation of the mammary tumor phenotype in wild-type erbB-2 transgenic mice was observed. Histologic tumor types and clinical aggressivity not reported previously in this transgenic model were noted, suggesting greater biologic heterogeneity than reported previously. In addition, dietary phytoestrogens modified mammary development and tumor latency, suggesting a need for greater stringency in dietary assignment for transgenic mouse models of mammary neoplasia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750262

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression.

Authors:  Natasha C Lucki; Marion B Sewer
Journal:  J Biol Chem       Date:  2011-04-14       Impact factor: 5.157

2.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

3.  Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.

Authors:  M H Herynk; M T Lewis; T A Hopp; D Medina; A Corona-Rodriguez; Y Cui; A R Beyer; S A W Fuqua
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

4.  Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

Authors:  Jennifer T Loud; Gretchen L Gierach; Timothy D Veenstra; Roni T Falk; Kathryn Nichols; Allison Guttmann; Xia Xu; Mark H Greene; Mitchell H Gail
Journal:  Breast Cancer Res Treat       Date:  2014-01-18       Impact factor: 4.872

5.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

Review 6.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

7.  Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells.

Authors:  Vikas Sehdev; James C K Lai; Alok Bhushan
Journal:  J Oncol       Date:  2010-02-11       Impact factor: 4.375

Review 8.  Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing.

Authors:  D Andrew Crain; Sarah J Janssen; Thea M Edwards; Jerrold Heindel; Shuk-mei Ho; Patricia Hunt; Taisen Iguchi; Anders Juul; John A McLachlan; Jackie Schwartz; Niels Skakkebaek; Ana M Soto; Shanna Swan; Cheryl Walker; Teresa K Woodruff; Tracey J Woodruff; Linda C Giudice; Louis J Guillette
Journal:  Fertil Steril       Date:  2008-10       Impact factor: 7.329

9.  Inhibition of Neu-induced mammary carcinogenesis in transgenic mice expressing ERΔ3, a dominant negative estrogen receptor α variant.

Authors:  Vicki L Davis; Firdos Shaikh; Katie M Gallagher; Michael Villegas; Sheri L Rea; J Mark Cline; Claude L Hughes
Journal:  Horm Cancer       Date:  2012-09-12       Impact factor: 3.869

10.  Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.

Authors:  Krisztina Kovács de Ostrovich; Isabel Lambertz; Jennifer K L Colby; Jie Tian; Joyce E Rundhaug; Dennis Johnston; Claudio J Conti; John DiGiovanni; Robin Fuchs-Young
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.